Genmab ADR (NASDAQ: GMAB) kicked off on Tuesday, down -3.17% from the previous trading day, before settling in for the closing price of $32.52. Over the past 52 weeks, GMAB has traded in a range of $17.24-$33.96.
Annual sales at Healthcare sector company grew by 28.01% over the past five years. While this was happening, its average annual earnings per share was recorded 8.01%. With a float of $615.99 million, this company’s outstanding shares have now reached $615.99 million.
Genmab ADR (GMAB) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Genmab ADR is 0.00%, while institutional ownership is 10.31%. The most recent insider transaction that took place on Dec 29 ’25, was worth 102,122,182. In this transaction 10% Owner of this company bought 1,052,806 shares at a rate of $97.00, taking the stock ownership to the 73,884,293 shares. Before that another transaction happened on Dec 26 ’25, when Company’s 10% Owner bought 2,978 for $97.00, making the entire transaction worth $288,866. This insider now owns 72,831,487 shares in total.
Genmab ADR (GMAB) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 0.84 earnings per share (EPS), higher than consensus estimate (set at 0.28) by 0.56. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 8.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.25% during the next five years compared to 28.01% growth over the previous five years of trading.
Genmab ADR (NASDAQ: GMAB) Trading Performance Indicators
Take a look at Genmab ADR’s (GMAB) current performance indicators. Last quarter, stock had a quick ratio of 6.01. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.40. Likewise, its price to free cash flow for the trailing twelve months is 15.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.35, a number that is poised to hit 0.43 in the next quarter and is forecasted to reach 1.57 in one year’s time.
Technical Analysis of Genmab ADR (GMAB)
Genmab ADR (NASDAQ: GMAB) saw its 5-day average volume 1.26 million, a negative change from its year-to-date volume of 1.61 million. As of the previous 9 days, the stock’s Stochastic %D was 45.21%.
During the past 100 days, Genmab ADR’s (GMAB) raw stochastic average was set at 80.95%, which indicates a significant increase from 21.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.58 in the past 14 days, which was higher than the 0.57 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.80, while its 200-day Moving Average is $25.07. Nevertheless, the first resistance level for the watch stands at $31.86 in the near term. At $32.23, the stock is likely to face the second major resistance level. The third major resistance level sits at $32.47. If the price goes on to break the first support level at $31.26, it is likely to go to the next support level at $31.02. Assuming the price breaks the second support level, the third support level stands at $30.65.
Genmab ADR (NASDAQ: GMAB) Key Stats
The company with the Market Capitalisation of 19.40 billion has total of 642,384K Shares Outstanding. Its annual sales at the moment are 3,121 M in contrast with the sum of 1,137 M annual income. Company’s last quarter sales were recorded 1,022 M and last quarter income was 401,000 K.
